Treatment with Standard and Low Dose of Conjugated Equine Estrogen Differentially Modulates Estrogen Receptor Expression and Response to Angiotensin II in Mesenteric Venular Bed of Surgically Postmenopausal Hypertensive Rats

Standard hormone therapy for menopausal women [conjugated equine estrogen (CEE) 0.625 mg] has been associated with increased risk of venous thrombosis. Regimens containing a lower CEE dose (0.30 mg) have been used clinically to decrease side effects of supraphysiologic doses of estrogen. In this study, we determined the effects of standard (SD) and low dose (LD) of CEE on venular function in ovariectomized (OVX) spontaneously hypertensive rats (SHR). Contractions by angiotensin-II (Ang-II 10 μM) in perfused mesenteric venular bed were markedly increased in OVX (21.5 ± 1.3 mmHg) compared with Sham (14.7 ± 1.1 mm Hg, P < 0.05). CEE-SD did not modify Ang-II responses in OVX, whereas CEE-LD restored Ang-II contraction to Sham levels. Endothelial nitric oxide synthase (eNOS) inhibition by L-NAME increased Ang-II contractions in Sham and CEE-LD and was without effect in venules of OVX SHR and CEE-SD. In OVX there was decreased NO generation in association with diminished eNOS phosphorylation and increased O2– generation in the venular wall. CEE-LD reverted the deleterious effects of ovariectomy. Although CEE-SD augmented eNOS phosphorylation in OVX, it was unable to increase NO levels, probably owing to its inability to reduce O2–. Distinct effects by CEE-SD and CEE-LD parallel the differential modulation of Ang-II and estrogen receptors. Compared with Sham, CEE-LD increases Ang II receptor type 2, whereas CEE-SD modified ERβ expression in the venous bed. Interestingly, both CEE doses increased G protein-coupled estrogen receptor in OVX. Our data suggest that estrogen dose is an important factor for venous function. Although CEE-LD reversed deleterious effects of OVX, CEE-SD showed null effects despite its ability to increase eNOS activity.

[1]  E. Prossnitz,et al.  Obligatory role for GPER in cardiovascular aging and disease , 2016, Science Signaling.

[2]  C. Shufelt,et al.  Hormone therapy in menopause: An update on cardiovascular disease considerations. , 2015, Trends in cardiovascular medicine.

[3]  Z. Fortes,et al.  Association of testosterone with estrogen abolishes the beneficial effects of estrogen treatment by increasing ROS generation in aorta endothelial cells. , 2015, American journal of physiology. Heart and circulatory physiology.

[4]  R. Santen.  Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels , 2015, Climacteric : the journal of the International Menopause Society.

[5]  L. Kooistra,et al.  Vaginal Cytology of the Laboratory Rat and Mouse , 2015, Toxicologic pathology.

[6]  D. Granger,et al.  Roles of Coagulation and Fibrinolysis in Angiotensin II‐Enhanced Microvascular Thrombosis , 2014, Microcirculation.

[7]  B. Psaty,et al.  Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers , 2014, Journal of thrombosis and haemostasis : JTH.

[8]  Z. Fortes,et al.  Conjugated equine estrogen treatment corrected the exacerbated aorta oxidative stress in ovariectomized spontaneously hypertensive rats , 2013, Steroids.

[9]  F. Lenfant,et al.  Key Role of Estrogens and Endothelial Estrogen Receptor &agr; in Blood Flow–Mediated Remodeling of Resistance Arteries , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[10]  E. Gold.  Bioidentical hormone therapy. , 2012, Canadian family physician Medecin de famille canadien.

[11]  S. Bowlin,et al.  A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women’s Health Initiative , 2012, Menopause.

[12]  T. Guzik,et al.  Targeting NADPH oxidases in vascular pharmacology. , 2012, Vascular pharmacology.

[13]  Z. Fortes,et al.  Vascular mechanisms involved in angiotensin II-induced venoconstriction in hypertensive rats , 2011, Peptides.

[14]  C. Hermenegildo,et al.  Aging Negatively Affects Estrogens-Mediated Effects on Nitric Oxide Bioavailability by Shifting ERα/ERβ Balance in Female Mice , 2011, PloS one.

[15]  E. Murphy.  Estrogen signaling and cardiovascular disease. , 2011, Circulation research.

[16]  E. Prossnitz,et al.  The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. , 2011, Vascular pharmacology.

[17]  L. Speroff,et al.  Low-dose hormone therapy in postmenopausal women in China , 2010, Climacteric : the journal of the International Menopause Society.

[18]  Richard E. White,et al.  Estrogen and oxidative stress: A novel mechanism that may increase the risk for cardiovascular disease in women , 2010, Steroids.

[19]  L. Speroff,et al.  Transdermal hormone therapy and the risk of stroke and venous thrombosis , 2010, Climacteric : the journal of the International Menopause Society.

[20]  A. Planas,et al.  Participation of Oxidative Stress on Rat Middle Cerebral Artery Changes Induced by Focal Cerebral Ischemia: Beneficial Effects of 3,4-Dihydro-6-hydroxy-7-methoxy-2,2-dimethyl-1(2H)-benzopyran (CR-6) , 2009, Journal of Pharmacology and Experimental Therapeutics.

[21]  M. Barton,et al.  ERalpha, ERbeta, and gpER: novel aspects of oestrogen receptor signalling in atherosclerosis. , 2009, Cardiovascular research.

[22]  M. Barton,et al.  Postmenopausal hypertension: mechanisms and therapy. , 2009, Hypertension.

[23]  X. Lu,et al.  Structure activity relationships and differential interactions and functional activity of various equine estrogens mediated via estrogen receptors (ERs) ERalpha and ERbeta. , 2008, Endocrinology.

[24]  A. Genazzani,et al.  Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. , 2008, Maturitas.

[25]  M. Barton,et al.  Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits? , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[26]  M. Franco,et al.  Enalapril and losartan restored blood pressure and vascular reactivity in intrauterine undernourished rats. , 2007, Life sciences.

[27]  Masato Matsuki,et al.  Nox1 Is Involved in Angiotensin II–Mediated Hypertension: A Study in Nox1-Deficient Mice , 2005, Circulation.

[28]  J. Szemraj,et al.  Angiotensin II enhances thrombosis development in renovascular hypertensive rats , 2005, Thrombosis and Haemostasis.

[29]  R. Baber,et al.  Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials , 2005, Climacteric : the journal of the International Menopause Society.

[30]  Z. Fortes,et al.  A lower ratio of AT1/AT2 receptors of angiotensin II is found in female than in male spontaneously hypertensive rats. , 2004, Cardiovascular research.

[31]  L. Ignarro,et al.  Estrogen-related receptor α1 up-regulates endothelial nitric oxide synthase expression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Mark Garton,et al.  Breast cancer and hormone-replacement therapy: the Million Women Study , 2003, The Lancet.

[33]  V. Beral.  Breast cancer and hormone-replacement therapy in the Million Women Study , 2003, The Lancet.

[34]  J. Gustafsson,et al.  Estrogen signaling: a subtle balance between ER alpha and ER beta. , 2003, Molecular interventions.

[35]  A. Genazzani,et al.  Postmenopausal femur bone loss: effects of a low dose hormone replacement therapy. , 2003, Maturitas.

[36]  R. Touyz.  Reactive oxygen species in vascular biology: role in arterial hypertension , 2003, Expert review of cardiovascular therapy.

[37]  L. Roberts,et al.  Characterization of an Animal Model of Postmenopausal Hypertension in Spontaneously Hypertensive Rats , 2003, Hypertension.

[38]  A. Genazzani,et al.  Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. , 2003, Maturitas.

[39]  P. Shaul,et al.  Estrogen modulation of endothelial nitric oxide synthase. , 2002, Endocrine reviews.

[40]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[41]  F. Hu,et al.  Postmenopausal hormone therapy and the risk of cardiovascular disease: the epidemiologic evidence. , 2002, The American journal of cardiology.

[42]  R. Lindsay,et al.  Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. , 2002, JAMA.

[43]  Z. Fortes,et al.  In Vivo Evidence for Antioxidant Potential of Estrogen in Microvessels of Female Spontaneously Hypertensive Rats , 2002, Hypertension.

[44]  A. Genazzani,et al.  Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. , 2001, American journal of obstetrics and gynecology.

[45]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[46]  F. Speizer,et al.  A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease , 2000, Annals of Internal Medicine.

[47]  E. Schiffrin,et al.  Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. , 2000, Pharmacological reviews.

[48]  A. G. González Ordóñez,et al.  Risk of venous thromboembolism associated with the insertion/deletion polymorphism in the angiotensin-converting enzyme gene , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[49]  L. Ghiadoni,et al.  Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women. , 2000, Circulation.

[50]  Z. Fortes,et al.  Influence of female sex hormones on endothelium-derived vasoconstrictor prostanoid generation in microvessels of spontaneously hypertensive rats. , 1999, Hypertension.

[51]  P. Sarrel,et al.  Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses. , 1998, The Journal of reproductive medicine.

[52]  Susan R. Johnson,et al.  Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .

[53]  R. Goetz,et al.  Increased expression of endothelial constitutive nitric oxide synthase in rat aorta during pregnancy. , 1994, Biochemical and biophysical research communications.

[54]  R W Alexander,et al.  Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. , 1994, Circulation research.

[55]  I. Charles,et al.  Induction of calcium-dependent nitric oxide synthases by sex hormones. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[56]  T. Warner.  Simultaneous perfusion of rat isolated superior mesenteric arterial and venous beds: comparison of their vasoconstrictor and vasodilator responses to agonists , 1990, British journal of pharmacology.

[57]  R. Lindsay,et al.  The Minimum Effective Dose of Estrogen for Prevention of Postmenopausal Bone Loss , 1984, Obstetrics and gynecology.

[58]  M. Fujishima,et al.  Effects of Acute Hypertension on Brain Metabolism in Normotensive, Renovascular Hypertensive and Spontaneously Hypertensive Rats , 1978, Stroke.

[59]  T. Lumley,et al.  Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. , 2014, JAMA internal medicine.

[60]  C. Christiansen,et al.  Prevention of early postmenopausal bone loss: controlled 2‐year study in 315 normal females , 1971, European journal of clinical investigation.

[61]  L. Ignarro,et al.  Estrogen-related receptor alpha 1 up-regulates endothelial nitric oxide synthase expression. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[62]  V. Beral.  Breast cancer and hormone-replacement therapy in the Million Women Study. , 2003, Lancet.

[63]  L. Ghiadoni,et al.  Endogenous estrogen and acetylcholine-induced vasodilation in normotensive women. , 1997, Hypertension.

[64]  R. Lindsay.  Criteria for successful estrogen therapy in osteoporosis , 1993, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.

[65]  A. E. Sheldon.  Effect of estrogen dose in postmenopausal bone loss. , 1984, The New England journal of medicine.